NASDAQ · Biotechnology

SEPN (SEPN) Stock

$33.89 +1.18% NASDAQ: SEPN Healthcare

Valuation

MetricValue
Price$33.89
Market Cap$1.53B
P/E Ratio-13.77
P/B Ratio4.30
P/S Ratio22.85
EPS (TTM)$-1.95
52-Week High$37.84
52-Week Low$10.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-9.26%
ROA-8.49%
ROCE-21.20%
Gross Margin99.42%
Operating Margin-77.07%
Net Margin-49.88%
Debt/Equity0.06
Current Ratio4.72

Annual Financials (USD)

Metric2022202320242025
Revenue—$0$1.0M$46.0M
Operating Profit—$2.0M$-81.0M$-81.0M
Net Profit—$4.0M$-72.0M$-49.0M
EPS—$0.03$-1.93$-1.10
Op Margin—1374.2%-7518.4%-175.8%

Balance Sheet (USD)

Metric2022202320242025
Total Assets$36.0M$131.0M$457.0M$596.0M
Total Liabilities$80.0M$169.0M$37.0M$214.0M
Cash$31.0M$88.0M$238.0M$121.0M
Borrowings$1.0M$13.0M$25.0M$24.0M

Latest News

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors? Motley Fool · Jul 5, 2026 Is Septerna, Inc. (SEPN) Stock a Biotech Opportunity With a Potential First-in-Class Hypoparathyroidism Treatment? Insider Monkey · Jul 2, 2026 Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares? Motley Fool · Jun 30, 2026 Guggenheim Initiates Septerna at Buy With $52 Price Target MT Newswires · Jun 11, 2026 Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting Business Wire · Jun 8, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-23.0M$-39.0M$-67.0M$110.0M
Investing Cash Flow$-3.0M$19.0M$-163.0M$-230.0M
Financing Cash Flow$0$0$0$0
Net Cash Flow$5.0M$58.0M$150.0M$-117.0M
Free Cash Flow$-25.0M$-42.0M$-70.0M$110.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-43.15
EV / EBITDA-19.47
FCF Yield6.48%
Quick Ratio4.71
Interest Coverage—
Return 1Y147.38%
Return 3Y—
Return 5Y—

Ownership

Insiders Held3.18%
Institutions Held102.63%
Institutions Float Held106.00%
Institutional HolderSharesReport Date
RA Capital Management, L.P.6,995,8582026-03-31
Trv Gp V, LLC 6,215,5912026-03-31
Driehaus Capital Management, LLC4,395,5722026-03-31
Trv Gp VI, LLC 4,211,6592026-03-31
Samsara BioCapital, LLC3,149,1282026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABUS $4.41 +0.00% -25.41 $871.14M 0.00%
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
FTRE $18.43 +4.18% -1.26 $1.75B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%

About SEPN

SEPN is led by CEO Jeffrey T. Finer, employs 75 people, headquartered in US, publicly traded since 2024.

SEPN stock trades at $33.89 with a market capitalization of $1.53B. The stock is valued at a price-to-earnings (P/E) ratio of -13.77, price-to-book of 4.30, price-to-sales of 22.85. Over the past 52 weeks the stock has ranged between $10.23 and $37.84, and currently trades 10.4% below its 52-week high.

On profitability, SEPN generates a return on equity (ROE) of -9.26%, return on capital employed of -21.20%, an operating margin of -77.07%, a net profit margin of -49.88%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides